Ocugen (NASDAQ:OCGN) Given “Buy” Rating at Chardan Capital

Ocugen (NASDAQ:OCGN)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock. Chardan Capital’s target price would indicate a potential upside of 258.06% from the company’s current price.

Several other research firms have also weighed in on OCGN. Canaccord Genuity Group assumed coverage on shares of Ocugen in a report on Tuesday, March 17th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright upped their price objective on shares of Ocugen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer initiated coverage on Ocugen in a research note on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Ocugen from a “sell” rating to a “hold” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ocugen has an average rating of “Moderate Buy” and a consensus target price of $9.75.

Ocugen Trading Up 1.8%

NASDAQ:OCGN traded up $0.04 during trading hours on Wednesday, hitting $1.96. 8,598,878 shares of the stock were exchanged, compared to its average volume of 7,992,266. The company has a market capitalization of $641.04 million, a P/E ratio of -8.50 and a beta of 2.75. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04. The company’s 50 day moving average is $1.73 and its two-hundred day moving average is $1.53. Ocugen has a twelve month low of $0.57 and a twelve month high of $2.73.

Ocugen (NASDAQ:OCGN) last issued its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. On average, sell-side analysts anticipate that Ocugen will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ocugen

A number of large investors have recently bought and sold shares of OCGN. Creative Planning bought a new stake in shares of Ocugen during the 2nd quarter worth approximately $57,000. XTX Topco Ltd bought a new stake in shares of Ocugen in the 2nd quarter valued at about $203,000. Rinkey Investments raised its holdings in shares of Ocugen by 1.2% in the 2nd quarter. Rinkey Investments now owns 1,179,006 shares of the company’s stock valued at $1,144,000 after purchasing an additional 14,500 shares during the period. Jump Financial LLC acquired a new stake in Ocugen in the 2nd quarter valued at about $57,000. Finally, Gerber Kawasaki Wealth & Investment Management bought a new position in Ocugen during the second quarter worth about $67,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

Ocugen News Summary

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised its price target to $10 and initiated/maintained a “buy” stance, citing upside versus current levels — this upgrade increases buy-side visibility and likely supported today’s buying interest. Benzinga
• Positive Sentiment: Ocugen reported topline 12?month Phase 2 ArMaDa results for OCU410 showing a statistically significant 31% reduction in GA lesion growth (optimal dose) vs. control, no treatment?related serious adverse events, and plans for a Phase 3 start in Q3 2026 — this is the primary long?term fundamental catalyst. Phase 2 Release
• Positive Sentiment: Index inclusion: Ocugen was added to the S&P Biotechnology Select Industry Index — increases institutional/ETF exposure and may boost demand from index?tracking funds. Yahoo Finance
• Positive Sentiment: Wall Street attention/targets: several recent analyst targets cluster around $10–$12 (median ~$10), and media pieces highlight a healthy cash position — both support a constructive medium?term view if trials proceed. Quiver / Analyst Notes
• Neutral Sentiment: Coverage highlighting Ocugen’s cash runway and recent R&D spend could be supportive but requires watching burn vs. upcoming Phase 3 costs. Yahoo – Cash Position
• Neutral Sentiment: Short?interest data in public feeds appears inconsistent/erroneous (zero/NaN entries); treat those reports cautiously — no clear short squeeze signal.
• Negative Sentiment: Some outlets reported an immediate share decline after the trial update (market underperformance/pullback), suggesting investors digested the results with caution — reasons include the need for confirmatory Phase 3 data, regulatory risk, and profit?taking after recent run?up. Seeking Alpha

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.